𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Onercept for Moderate-to-Severe Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial

✍ Scribed by Rutgeerts, Paul; Sandborn, William J.; Fedorak, Richard N.; Rachmilewitz, Daniel; Tarabar, Dino; Gibson, Peter; Haagen Nielsen, Ole; Wild, Gary; Schreiber, Stefan; Pena Rossi, Claudia

Book ID
123445710
Publisher
Elsevier Science
Year
2006
Tongue
English
Weight
101 KB
Volume
4
Category
Article
ISSN
1542-3565

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn's disease
✍ J. P. Wright; Dr. D. P. Jewell; R. Modigliani; H. Malchow 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 486 KB 👁 2 views

Olsalazine, consisting of two salicylate radicals linked by an azo-bond, is effective in the treatment of active ulcerative colitis. To test its effect in patients with mild to moderate attacks of Crohn's disease, the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) des

Fontolizumab in moderate to severe Crohn
Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study
✍ Walter Reinisch; Williem de Villiers; László Bene; László Simon; István Rácz; Se 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 285 KB

## Background: The safety and efficacy of fontolizumab, a humanized anti-interferon gamma antibody, was investigated in patients with Crohn's disease (CD). Elevated gut mucosal levels of interferon gamma, a key cytokine involved in the inflammatory process of CD, are associated with disease symptom